These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6785242)

  • 21. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.
    Gilleland HE; Parker MG; Matthews JM; Berg RD
    Infect Immun; 1984 Apr; 44(1):49-54. PubMed ID: 6323316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective mechanism of the immune response to a ribosomal vaccine from Pseudomonas aeruginosa. I. In vivo protection studies in compromised animal models.
    Lieberman MM; Frank WJ
    J Surg Res; 1988 Mar; 44(3):242-50. PubMed ID: 3125388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Fomsgaard A; Høiby N; Shand GH; Conrad RS; Galanos C
    Infect Immun; 1988 Sep; 56(9):2270-8. PubMed ID: 3410536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis.
    Weisner AM; Chart H; Bush A; Davies JC; Pitt TL
    J Med Microbiol; 2007 May; 56(Pt 5):670-674. PubMed ID: 17446292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunologic study of artificial complex antigens obtained from P. aeruginosa lipopolysaccharides].
    Edvabnaia LS; Stanislavskiĭ ES; Kolker II; Grishina IA; Zarubina EK
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Sep; (9):36-41. PubMed ID: 115186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
    Preston MJ; Gerçeker AA; Reff ME; Pier GB
    Infect Immun; 1998 Sep; 66(9):4137-42. PubMed ID: 9712759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against lethal infection of Pseudomonas aeruginosa.
    Bruderer U; Fürer E; Cryz SJ; Lang AB
    Res Immunol; 1992 Feb; 143(2):165-74. PubMed ID: 1374194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibodies that distinguish inner core, outer core, and lipid A regions of Pseudomonas aeruginosa lipopolysaccharide.
    de Kievit TR; Lam JS
    J Bacteriol; 1994 Dec; 176(23):7129-39. PubMed ID: 7525538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
    van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
    Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
    Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
    J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
    [No Abstract]   [Full Text] [Related]  

  • 32. [An antigenic analysis and the protective properties of the R-form lipopolysaccharides of gram-negative bacteria].
    Stanislavskiĭ ES; Makarenko TA; Kholodkova EV; Lugowski C
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):52-6. PubMed ID: 9783402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.
    Collins MS; Roby RE
    Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.
    Lieberman MM
    Infect Immun; 1978 Jul; 21(1):76-86. PubMed ID: 101464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an enzyme-linked immunosorbent assay for studying Pseudomonas aeruginosa cell surface antigens.
    Borowski RS; Stock LM; Schiller NL
    J Clin Microbiol; 1984 Jun; 19(6):736-41. PubMed ID: 6206085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinable Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.
    Fomsgaard A; Conrad RS; Galanos C; Shand GH; Høiby N
    J Clin Microbiol; 1988 May; 26(5):821-6. PubMed ID: 3133386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Immunogenicity and Protective Efficacy of a
    Ryu JI; Wui SR; Ko A; Lee YJ; Do H; Kim HJ; Rhee IM; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2017 Aug; 27(8):1539-1548. PubMed ID: 28621112
    [No Abstract]   [Full Text] [Related]  

  • 39. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism for pulmonary protection by lipopolysaccharide pseudomonas vaccine.
    Pennington JE; Kuchmy D
    J Infect Dis; 1980 Aug; 142(2):191-8. PubMed ID: 6774032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.